MSD announces pembrolizumab meets one of primary endpoints in phase III KEYNOTE-204 trial in in patients with relapsed or refractory classical Hodgkin lymphoma

Pembrolizumab demonstrated a statistically significant improvement in progression-free survival vs. brentuximab vedotin. The other dual endpoint, overall survival, was not formally tested at this interim analysis, but study is reported to continue to evaluate this endpoint.